NCT00829127 - AZD8075 Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Oral Doses of AZD8075 in Healthy Male Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions

Healthy

Interventions

DRUG

AZD8075

single dose, oral suspension, on Day 1. Repeated dosing will commence on Day 3 once daily for 14 days. The planned starting dose will be 35 mg with up to 2 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits or the exposure obtained so far in the SAD study.

DRUG

Placebo

Oral suspension